Article

Bausch + Lomb: The Experts in the Evolution of Bromfenac

Partner Perspectives
What is this?

×

Partner Perspectives allows marketers to connect directly with the Ophthalmology Times audience by enabling them to share their content. This content does not necessarily reflect the views of Ophthalmology Times editorial staff or UBM.

Learn more

Become a partner

PROLENSA® (bromfenac ophthalmic solution) 0.07%

Please see Indication and Important Safety Information for PROLENSA® on video.

Contact us: In order to provide more personalized service, we ask that you report any concerns with Bausch + Lomb Products via phone at 800-553-5340.

Product Concerns: 800-553-5340

Order Inquiries for professionals: 800-828-9030

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.